A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Completed
Janssen Research & Development, LLC
Phase 2
The purpose of this study is to determine the overall cutaneous response rate (participants
who achieve a complete response or partial response) based on the modified severity weighted
assessment tool criteria.
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Completed
Janssen Pharmaceutica N.V., Belgium
Phase 1
Quisinostat besides its own efficacy, which can potentially lead to better results of
polychemotherapy and increase the mean time to progression, it may be demonstrated that
Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and
tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg
combined with standard backbone chemotherapy in patients with non-small cell lung cancer
(second line) and ovarian cancer (second and subsequent lines) will be investigated.
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy
Completed
NewVac LLC
Phase 1
Quisinostat besides its own efficacy, which can potentially lead to better results of
polychemotherapy and increase the mean time to progression, it may be demonstrated that
Quisinostat leads to sustained tumor sensitivity to platinum drugs. In this study safety and
tolerability of multiple administrations of Quisinostat in doses ranging from 8 mg to 12 mg
combined with standard backbone chemotherapy in patients with non-small cell lung cancer
(second line) and ovarian cancer (second and subsequent lines) will be investigated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
